Yeah I’m not sure of the distinction between the different classifications - it does sound like there is overlap. Fast track allows more interaction, think priority review is for a yes/no for approval more quickly is my quick reading of it - someone else can add more nuance if they’d like to.
the point I was making is I don’t think Imugene will get a voucher - it’s for tropical, rare paediatric, and medical countermeasures only, other things for cancer I guess, like accelerated approval etc?
Media Thread, page-11224
-
- There are more pages in this discussion • 3,895 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |